Adimab Announces Technology Transfer Agreement with Merck – Fourth Company to Internalize the Platform

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it has entered into a definitive agreement with Merck, known as MSD outside the United States and Canada, to transfer Adimab’s antibody technology to Merck Research Laboratories for the discovery and optimization of monoclonal and [...]

By | January 12th, 2016|Dartmouth Innovation, News|

Adimab Provides Update on Recent Partnerships and Milestones

Adimab, LLC, the global leader in the discovery and optimization of fully human monoclonal and bispecific antibodies, today announced that it has entered into definitive agreements with several new companies, as well as expanded partnerships with several of its current partners. In addition, Adimab announced the achievement of technical and development milestones under a number [...]

By | January 11th, 2016|New Hampshire|